A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together
This study assesses the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with capecitabine in patients with advanced solid tumors
Solid Tumors|Breast Cancer|Neoplasms
DRUG: SU011248; Capecitabine
To determine the maximally tolerated dose of SU011248 (dosed continuously or on a 4/2 or 2/1 Schedule) when given in combination with capecitabine., From Screening until disease progression or discontinuation of the study
To evaluate the pharmacokinetics of SU011248 and capecitabine when these drugs are co-administered, From Cycle 1, Day 1 until discontinuation of the study|To preliminarily assess the antitumor activity of SU011248 and capecitabine in patients with measurable disease, From screening until disease progression or discontinuation of the study
This study assesses the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with capecitabine in patients with advanced solid tumors